DOFETILIDE PACKAGE INSERT PDF
Dofetilide (Tikosyn) Considerations for Use*. US/FDA Special Notes. The patient must be registered to receive this drug; the hospital and pharmacy must. Easy to read FDA package insert, drug facts, dosage and administration, and adverse effects for Tikosyn (Dofetilide). (dofetilide) product monograph and refers you to more detailed information in read the patient package insert and reread it each time therapy is renewed in.
|Published (Last):||6 February 2011|
|PDF File Size:||20.85 Mb|
|ePub File Size:||3.75 Mb|
|Price:||Free* [*Free Regsitration Required]|
Severe Tacrolimus prolongs the QTc interval.
Higher antiarrhythmic plasma concentrations increases the insfrt risk of QT prolongation, TdP or other proarrhythmias. Coadministration may result in additive effects on the QT interval, further increasing the risk of serious adverse events e. Clinical trial data indicate that ziprasidone causes QT prolongation; there are postmarketing reports of TdP in patients with multiple confounding factors.
Severe Pazopanib has been reported to prolong the QT interval. Because of the potential for TdP, use of fluoxetine ijsert dofetilide is contraindicated. It is prudent to avoid the use of any thiazide diuretic in combination with dofetilide.
Erythromycin administration is associated with QT prolongation and TdP. Darunavir; Cobicistat; Emtricitabine; Tenofovir alafenamide: Severe Because of the potential for torsade de pointes TdPuse of sertraline with dofetilide is contraindicated. Conivaptan has been associated with hypokalemia 9. This effect, and the related increase in effective refractory period, is observed in the atria and ventricles in electrophysiology studies. Moderate Use lacosamide with caution in patients taking concomitant medications that affect cardiac conduction, such as Class III antiarrhythmics, because of the risk of AV block, bradycardia, or ventricular tachyarrhythmia.
Moderate Monitor for an increase in dofetilide-related adverse reactions, including QT prolongation, if coadministration with amlodipine is necessary. Individualize dosage based on renal function and QTc in a monitored facility.
Severe Because of the potential for torsades de pointes TdPconcurrent use of artemether; lumefantrine and dofetilide is contraindicated. Romidepsin has been reported to prolong the QT interval.
Minor Coadministration of dofetilide with inducers of CYP3A4, such as nevirapine, may increase the metabolism of dofetilide. Pakage Lamivudine; Tenofovir Disoproxil Fumarate: Although no study specifically investigated this risk, in post-trial analyses, no increase in mortality was observed in females receiving dofetilide vs.
Dofetilide is associated with a well-established risk of QT prolongation and TdP. Increases in QTc interval have been observed in healthy volunteers treated with packge, and torsade de pointes has been reported in patients receiving sparfloxacin with disopyramide and amiodarone. Corticosteroid-induced hypokalemia could also enhance the proarrhythmic effects of dofetilide. Because of the potential for QT prolongation or TdP, concurrent use is contraindicated.
Competition for renal elimination may increase plasma concentrations of dofetilide and increase the risk of pro-arrhythmias. In hemodynamic studies, dofetilide had no dofetllide on cardiac output, cardiac index, stroke volume index, or systemic vascular resistance in patients with ventricular tachycardia, mild insret moderate congestive heart failure or angina and either normal or low left ventricular ejection fraction.
Dialysis, renal disease, renal failure, renal impairment. Moderate A clinically relevant increase in the plasma concentration dofetildie dofetilide may occur if given with letermovir; monitor patient closely for dofetilide-related adverse events. Severe Potential QT prolongation has been inset in limited case reports with metronidazole. The effect of vardenafil on the QT interval should be considered when prescribing the drug. According to the manufacturer, Class I disopyramide, encainide, flecainide, lidocaine, mexiletine, moricizine, procainamide, propafenone, quinidine, and tocainide antiarrhythmic agents are associated with QT prolongation and ventricular arrhythmias and concurrent exposure with dofetilide could increase the risk of dofetilide-induced proarrhythmias.
Dofetilide is associated with a well-established risk of QT prolongation and torsades de pointes TdP. Bictegravir; Emtricitabine; Tenofovir Alafenamide: As with other drugs that cause TdP, dofetilide was associated with a greater risk of TdP in females than in males. Because of the potential for TdP, use of dofetilide with norfloxacin innsert contraindicated.
Major Hypokalemia may occur with administration of potassium-depleting drugs such as conivaptan, increasing the potential for dofetilide-induced torsade de pointes.
Isavuconazonium inhibits the renal organic cation transporter OCT2, and dofetilide is eliminated via this transporter. Dofetilide should not be used in patients with a baseline QT interval or QTc greater than msec msec in patients with ventricular conduction abnormalities. Careful patient monitoring and dose adjustment of metformin and dofetilide is recommended.
Azithromycin has been associated with cases of QT prolongation and TdP, reported during the post-marketing period. Dofetilide plasma concentrations are linearly related to drug dosage.
Severe Thioridazine is associated with a well-established risk of QT prolongation and torsades de pointes TdP. Moderate Monitor for an increase in dofetilide-related adverse reactions, including QT prolongation, if coadministration with everolimus is necessary.
Severe Some quinolones, including ofloxacin, have been associated with QT prolongation and infrequent cases of arrhythmia. Severe Because of the potential for torsade de pointes TdPuse of panobinostat with dofetilide is contraindicated. Severe Because of the increased risk for QT prolongation and torsade de pointes TdPthe use of dofetilide with ondansetron is contraindicated. Severe Because of the potential for torsade de pointes TdPuse of toremifene with dofetilide is contraindicated.
Because of the potential for TdP, use of atomoxetine with dofetilide is contraindicated. Due to selective and potent blockade of potassium channels, dofetilide prolongs ventricular refractoriness i. This interaction may result in increased dofetilide plasma concentrations and risk for QTc prolongation. Because of the potential for TdP, use of dofetilide with metronidazole is contraindicated. These reports generally involved patients with concurrent medical conditions or concomitant medications that may have been contributory.
The manufacturer recommends using actual body weight in the Cockcroft-Gault equation to calculate creatinine clearance. Because of the potential for TdP, use of dofetilide with paliperidone is contraindicated. Sorafenib has also been associated with QT prolongation.
Severe Because of the potential for torsades de pointes TdPuse of pasireotide and dofetilide is contraindicated.